SIRT1 and triple-negative breast carcinoma: Fatehi et al. demonstrated that these triple negative breast cancer cells were most radiosensitised when pre-treated with interlukin-6, sirtuin 1 (SIRT1) activator (SRT1720), NVP-BEZ235 [63].